The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis
- PMID: 15003896
The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis
Abstract
Background and objectives: The purpose of this study was to assess the incidence of central venous catheter (CVC)-related thrombosis and the contribution of two common inherited coagulation disorders (factor V Leiden, prothrombin G20210A mutation) to this complication in a large hospital population.
Design and methods: In a prospective setting, patients were assessed daily for signs and symptoms suggestive of thrombosis. Routine Doppler-ultrasound was performed weekly in all patients until CVC removal. Doppler-ultrasound examinations were stored on videotape and assessed by two blinded observers. In the case of clinically suspected thrombosis the physicians followed routine diagnostic and therapeutic procedures. The presence of factor V Leiden and prothrombin G20210A mutation and other potential risk factors were assessed in all patients.
Results: In 252 consecutive patients the cumulative incidence of-CVC related thrombosis was 30% (clinically manifested thrombosis: 7%). The relative risk of factor V Leiden or prothrombin G20210A mutation for thrombosis was 2.7 (CI95% 1.9 to 3.8). In addition, a personal history of venous thrombosis was associated with CVC-related thrombosis, whereas the severity of thrombosis was affected by the absence of anticoagulants and the presence of cancer.
Interpretation and conclusions: Thrombosis is frequently observed after central venous catheterization. Common inherited abnormalities in blood coagulation contribute substantially to CVC-related thrombosis. In view of physicians' reluctance to prescribe prophylactic anticoagulant treatment in vulnerable patients, a priori determination of common inherited and acquired risk factors may form a basis to guide these treatment decisions.
Similar articles
-
Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients.Bone Marrow Transplant. 2005 Nov;36(10):885-9. doi: 10.1038/sj.bmt.1705156. Bone Marrow Transplant. 2005. PMID: 16151418
-
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.Thromb Haemost. 2002 Apr;87(4):580-5. Thromb Haemost. 2002. PMID: 12008938 Clinical Trial.
-
Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations.Blood Coagul Fibrinolysis. 2010 Jan;21(1):11-5. doi: 10.1097/MBC.0b013e32832d6ce7. Blood Coagul Fibrinolysis. 2010. PMID: 19474699
-
Thrombophilia as a multigenic disease.Haematologica. 1999 Jan;84(1):59-70. Haematologica. 1999. PMID: 10091393 Review.
-
Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism.Semin Thromb Hemost. 2000;26(3):305-11. doi: 10.1055/s-2000-8473. Semin Thromb Hemost. 2000. PMID: 11011848 Review.
Cited by
-
Incidental catheter-associated upper extremity deep venous thrombosis detected by point-of-care ultrasound.BMJ Case Rep. 2021 Aug 26;14(8):e244357. doi: 10.1136/bcr-2021-244357. BMJ Case Rep. 2021. PMID: 34446517 Free PMC article. No abstract available.
-
Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study.Cancer Med. 2017 Nov;6(11):2732-2744. doi: 10.1002/cam4.1201. Epub 2017 Oct 4. Cancer Med. 2017. PMID: 28980454 Free PMC article.
-
Venous thromboembolism in hematopoietic stem cell transplant recipients.Bone Marrow Transplant. 2016 Apr;51(4):473-8. doi: 10.1038/bmt.2015.308. Epub 2015 Dec 21. Bone Marrow Transplant. 2016. PMID: 26691425 Review.
-
A systematic review of patient-related risk factors for catheter-related thrombosis.J Thromb Thrombolysis. 2015 Oct;40(3):363-73. doi: 10.1007/s11239-015-1175-9. J Thromb Thrombolysis. 2015. PMID: 25680892 Review.
-
Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report.BMC Urol. 2015 Mar 17;15:21. doi: 10.1186/s12894-015-0011-z. BMC Urol. 2015. PMID: 25887618 Free PMC article.